



# Improved left atrial catheterization efficiency and consistency using a novel steerable transseptal puncture sheath

## HIGHLIGHTS

- ▶ Using the **VersaCross™** Steerable Access Solution (steerable sheath + RF wire) for both transseptal puncture (TSP) and radiofrequency (RF) ablation procedures in atrial fibrillation patients is safe and efficient.
- ▶ Compared to the standard workflow (fixed curve sheath + RF needle, then exchange to a steerable sheath), the zero-exchange VersaCross Steerable workflow resulted in:
  - 34% faster time to TSP from venous access.
  - 40% faster left atrial (LA) catheterization.
  - 14.2 minutes (min) faster overall procedure time.

## INTRODUCTION

- ▶ Steerable sheaths offer optimal contact force during RF catheter ablation, yet their usage for TSP has not been evaluated in terms of safety and workflow efficiency.
- ▶ This study compared LA catheterization and ablation time of a RF wire-based steerable transseptal system to the standard needle-based workflow.

## METHODS

- ▶ Single-center, retrospective study of 30 consecutive patients with atrial fibrillation (AF) undergoing low fluoro/fluorless RF ablation.
- ▶ **Standard workflow (n=15):**
  - TSP performed using an 8.5F **TorFlex™** Fixed Sheath (Boston Scientific) and **NRG™** RF Needle (Boston Scientific).
  - **ProTrack™** Pigtail Wire (Boston Scientific) used to exchange the transseptal assembly for the Agilis™ Steerable Sheath (Abbott).
- ▶ **VersaCross Steerable workflow (n=15):**
  - VersaCross Steerable Access Solution, comprised of a pigtail RF wire and steerable sheath, was used to perform TSP and ablation with no sheath exchanges.
- ▶ TSP and catheter manipulations were guided by intracardiac echocardiography (ICE) and electroanatomic mapping (EAM) using the CARTO 3 System (Biosense Webster).
- ▶ **Primary endpoint:** Time to TSP and steerable sheath access into the LA.
- ▶ **Secondary endpoint:** RF ablation time, LA dwell time, acute procedural success, procedure time, procedural complications, and fluoroscopy use.

## RESULTS

### LA Access

- ▶ 34% faster time to TSP from venous access with VersaCross Steerable workflow vs. standard workflow (Figure 1A).
  - Less variability between cases in the VersaCross group.
- ▶ 40% faster steerable sheath placement in the LA with VersaCross Steerable workflow vs. standard workflow (Figure 1B).

### RF Ablation

- ▶ Acute procedural success was achieved in all patients with no complications and comparable LA dwell time.
- ▶ Overall procedure time was shorter in the VersaCross Steerable workflow vs. standard workflow (Figure 1C).
- ▶ No difference in fluoroscopy use between groups.




Figure 1. Improved workflow efficiency using VersaCross Steerable workflow vs. standard workflow.

## DISCUSSION AND CONCLUSIONS

- ▶ The VersaCross Steerable Access Solution streamlined the ablation workflow by eliminating 4 procedural steps leading to a faster overall ablation procedure.
- ▶ The atraumatic pigtail wire and rounded dilator tip support direct puncture with a steerable sheath without compromising safety compared to standard steerable sheaths and needles.

## Brief Summary | **NRG™** Transseptal Needle

**CAUTION:** Federal law (USA) restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete "Instructions for Use" for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator's Instructions.

**INDICATIONS FOR USE:** The NRG™ Transseptal Needle is used to create an atrial septal defect in the heart. Secondary indications include monitoring intracardiac pressures, sampling blood, and infusing solutions.

**CONTRAINDICATIONS:** The NRG™ Transseptal Needle is not recommended for use with any conditions that do not require cutting or coagulation of soft tissue.

**WARNINGS:** • Laboratory staff and patients can undergo significant x-ray exposure during radiofrequency puncture procedures due to the continuous usage of fluoroscopic imaging. This exposure can result in acute radiation injury as well as increased risk for somatic and genetic effects. Therefore, adequate measures must be taken to minimize this exposure. • The NRG™ Transseptal Needle is intended for single patient use only. Do not attempt to sterilize and reuse the needle. Reuse can cause the patient injury and/or the communication of infectious disease(s) from one patient to another. Failure to do so may result in patient complications. • The NRG™ Transseptal Needle must be used with the BMC Connector Cable. Attempts to use it with other connector cables can result in electrocution of the patient and/or operator.

**PRECAUTIONS:** • Placement of the dispersive electrode on the thigh or hip could be associated with higher impedance. • In order to prevent the risk of ignition make sure that flammable material is not present in the room during RF power application. • Careful needle manipulation must be performed to avoid cardiac damage, or tamponade. Needle advancement should be done under image guidance. If resistance is encountered, DO NOT use excessive force to advance or withdraw the needle. • During power delivery, the patient should not be allowed to come in contact with ground metal surfaces. • Thoroughly flush the NRG™ Transseptal Needle with heparinized saline solution prior to use. • If using electroanatomical mapping guidance it is recommended to confirm tip placement on the fossa ovalis and septal tenting before RF puncture with graphic imaging or another imaging modality.

**ADVERSE EVENTS:** Adverse events that may occur while using the Baylis Medical Radiofrequency Puncture System include: • Tamponade • Sepsis/Infection • Thromboembolic episodes • Vessel perforation • Atrial Fibrillation • Myocardial Infarction • Vessel spasm • Sustained arrhythmias • Atrial Flutter • Hemorrhage • Vascular thrombosis • Perforation of the myocardium • Hematoma • Allergic reaction to contrast medium • Ventricular Tachycardia • Pain and Tenderness • Thermal damage to tissue • Arteriovenous fistula • Pericardial Effusion

EP-1506305-AA

## Brief Summary | **TorFlex™** Transseptal Guiding Sheath

**CAUTION:** Federal law (USA) restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete "Instructions for Use" for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator's Instructions.

**INDICATIONS FOR USE:** The TorFlex™ Transseptal Guiding Sheath kit is used for the percutaneous introduction of various types of cardiovascular catheters and guidewires to all heart chambers, including the left atrium via transseptal perforation / puncture.

**CONTRAINDICATIONS:** There are no known contraindications for this device.

**WARNINGS:** • Laboratory staff and patients can undergo significant x-ray exposure during interventional procedures due to the continuous usage of fluoroscopic imaging. This exposure can result in acute radiation injury as well as increased risk for somatic and genetic effects. Therefore, adequate measures must be taken to minimize this exposure. The use of echocardiography is recommended. • The TorFlex™ Transseptal Guiding Sheath kit is intended for single patient use only. Do not attempt to sterilize and reuse the TorFlex™ Transseptal Guiding Sheath kit. Reuse can cause patient injury and/or the communication of infectious disease(s) from one patient to another. • Care should be taken to ensure that all air is removed from the sheath before infusing through the side port. • Do not attempt direct percutaneous insertion of the sheath without the dilator as this may cause vessel injury. • Careful manipulation must be performed to avoid cardiac damage or tamponade. Sheath advancement should be done under fluoroscopic guidance. Echocardiographic guidance is also recommended.

**PRECAUTIONS:** • Careful manipulation must be performed to avoid cardiac damage, or tamponade. Sheath, dilator and guidewire advancement should be done under fluoroscopic guidance. If resistance is encountered, DO NOT use excessive force to advance or withdraw the device.

**ADVERSE EVENTS:** Adverse events that may occur while using the TorFlex™ Transseptal Guiding Sheath kit include: • Infection • Air embolus • Local nerve damage • Hemorrhage • Embolic events • Vessel spasm • AV fistula formation • Atrial septal defect • Pseudoaneurysm • Perforation and/or tamponade • Arrhythmias • Pericardial/pleural effusion • Hematoma • Vessel trauma • Valve damage • Catheter entrapment

EP-1515406-AA

## Brief Summary | **ProTrack™** Pigtail Wire

**CAUTION:** Federal law (USA) restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete "Instructions for Use" for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator's Instructions.

**INDICATIONS FOR USE:** The ProTrack™ Pigtail Wires are intended for use in percutaneous transseptal procedures to introduce and position catheters and other interventional devices within the left heart. The device is not intended for use in the coronary arteries.

**CONTRAINDICATIONS:** There are no known contraindications for this device.

**WARNINGS:** • DO NOT push, auger, withdraw or torque a pigtail wire against resistance until the cause of the resistance has been determined. Applying excessive force against unexpected resistance may cause damage to the pigtail wire, interventional device and/or vessel/organ. • When the pigtail wire is exposed to the vascular system, it should be manipulated while under high-resolution imaging guidance including fluoroscopy and/or echocardiography. Improper visualization of the guidewire may lead to misplacement, dissection, or perforation. • Inspect the pigtail wire prior to use for coil separation, kinking, appropriate distal tip flexibility or breakage. If the pigtail wire is damaged or defective, do not use it. Using a damaged or defective pigtail wire may cause vasculature damage and/or compromise pigtail wire performance. • Laboratory staff and patients can undergo significant X-ray exposure during interventional procedures due to the continuous usage of fluoroscopic imaging. The exposure can result in acute radiation injury as well as increased risk for somatic and genetic effects. Therefore, adequate measures must be taken to minimize this exposure.

**ADVERSE EVENTS:** Potential complications associated with the use of the pigtail wire include, but are not limited to: • Vessel Perforation/Dissection/Trauma or Damage • Vessel Spasm • Hemorrhage • Access Site Complications/Hematoma • Thrombus/Thromboembolism • Allergic reaction • Vascular complication • Cardiac tamponade • Cardiac Perforation/Laceration • Conduction disorder • Embolism • Additional Surgical Procedure • Pericardial/pleural effusion • Sepsis/Infection/Inflammation • Foreign Body/Wire Fracture • Hemolysis • Hypovolemia • Myocardial Ischemia and/or Infarction • Stroke/Transient Ischemic Attack • Vessel Occlusion • Wire Entrapment/Entanglement • Valve Complication

EP-1515204-AA

## Brief Summary | **VersaCross™** Steerable Sheath

**CAUTION:** Federal law (USA) restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete "Instructions for Use" for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator's Instructions.

**INDICATIONS FOR USE:** The VersaCross™ Steerable Sheath kit is indicated for introducing various cardiovascular catheters to the heart, including the left side of the heart through the interatrial septum.

**CONTRAINDICATIONS:** There are no known contraindications for this device.

**WARNINGS:** • Laboratory staff and patients can undergo significant x-ray exposure during interventional procedures due to the continuous usage of fluoroscopic imaging. This exposure can result in acute radiation injury as well as increased risk for somatic and genetic effects. Therefore, adequate measures must be taken to minimize this exposure. The use of echocardiography is recommended. • The VersaCross Steerable Sheath kit is intended for single patient use only. Do not attempt to sterilize and reuse the VersaCross Steerable Sheath kit. Reuse can cause the patient injury and/or the communication of infectious disease(s) from one patient to another. • Care should be taken to ensure that all air is removed from the sheath before infusing through the side port. • Care should be taken when inserting or removing the dilator and catheters from the sheath. • Do not attempt direct percutaneous insertion of the sheath without the dilator as this may cause vessel injury. • Maintain continuous hemodynamic monitoring throughout procedure. • Provide continuous heparinized saline infusion while the introducer remains in vessel. • To minimize vacuum effects during withdrawal, remove components/aspirate slowly. Refrain from aspiration if a wire is directly through the valve. • Avoid contact with liquids other than blood, isopropyl alcohol, contrast solution or saline. • Prior to steerable sheath's delivery and removal, ensure distal section is as straight as possible. • Do not kink, stretch or severely bend steerable sheath. • Do not use surgical instruments to handle sheath. • The sheath device shaft in its entirety is coated with a hydrophobic lubricious coating for smoother device manipulation. The following warning must be considered: o Excessive wiping and/or wiping with a dry gauze may damage the coating. • The guidewire is coated with a lubricious coating. The following warnings must be considered: o Use with incompatible introducers or dilators may affect device performance and integrity, including coating integrity. o Excessive manual bending and/or shaping of the device may affect the coating integrity. • DO NOT attempt to insert or retract the guidewire through a metal cannula or a percutaneous needle, which may damage the guidewire and may cause patient injury.

**PRECAUTIONS:** • Do not attempt to use the VersaCross Steerable Sheath kit before thoroughly reading the accompanying Instructions for Use. • Careful manipulation must be performed to avoid cardiac damage, or tamponade. Sheath, dilator and guidewire advancement should be done under fluoroscopic guidance. If resistance is encountered, DO NOT use excessive force to advance or withdraw the device. • The VersaCross Steerable Sheath kit is supplied STERILE using an ethylene oxide process. • The sterile packaging and all components should be visually inspected prior to use. Do not use if the device, packaging or sterile barrier have been compromised or damaged. • Only physicians thoroughly trained in the techniques of the approach to be used should perform interventional procedures. • Do not use device after its "Use By" date. • Avoid deflecting distal end of sheath during delivery and removal, otherwise damage to vessels may occur. • The VersaCross Steerable Sheath kit is not compatible with transseptal needles such as the "NRG™ Transseptal Needle". • Do not reshape distal tip or curve of the guidewire. Excessive bending or kinking of the distal curve may damage the integrity of the wire or coating and lead to patient injury. • Only use compatible tip straighteners with the guidewire. • Do not attempt to insert the proximal end of the guidewire as the distal end. • Confirm ancillary devices are compatible with the dilator and guidewire diameters before use. • Individual patient anatomy and physician technique may require procedural variations. • Do not attempt to use the guidewire with electrocautery tools. • Avoid guidewire contact with liquids other than blood, isopropyl alcohol, contrast solution or saline.

**ADVERSE EVENTS:** Adverse events that may occur while using the VersaCross™ Sheath include: • Infection • Air embolus • Local nerve damage • Vasovagal reaction • Dissection • Vessel spasm • AV fistula formation • Atrial septal defect • Pseudoaneurysm • Aortic puncture • Arrhythmias • Perforation and/or tamponade • Hematoma • Hemorrhage • Catheter entrapment • Embolic events • Stroke • Valve damage • Myocardial infarction • Pericardial/pleural effusion • Pulmonary edema • Coronary artery spasm and/or damage • Vessel trauma • Pacemaker/defibrillator lead displacement

97184084 (REV. A)

## Brief Summary | VersaCross™ RF Wire

**CAUTION:** Federal law (USA) restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete "Instructions for Use" for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator's Instructions.

**INDICATIONS FOR USE:** The VersaCross™ RF Wire is indicated for creation of an atrial septal defect in the heart.

**CONTRAINDICATIONS:** The VersaCross™ RF Wire is not recommended for use with any conditions that do not require the creation of an atrial septal defect. The Connector Cable is not recommended for use with any other Baylis RF Generator or any other device.

**WARNINGS:** • Only physicians with a thorough understanding of angiography and percutaneous interventional procedures should use this device. It is recommended that physicians avail themselves of pre-clinical training, a review of pertinent literature and other appropriate education before attempting new interventional procedures. • The VersaCross RF Wire and Connector Cable are supplied STERILE using an ethylene oxide process. Do not use if the package is damaged. • Laboratory staff and patients can undergo significant x-ray exposure during RF puncture procedures due to the continuous usage of fluoroscopic imaging. This exposure can result in acute radiation injury as well as increased risk for somatic and genetic effects. Therefore, adequate measures must be taken to minimize this exposure. • The VersaCross RF Wire and Connector Cable are intended for single patient use only. Do not attempt to sterilize and reuse either device. Reuse can cause patient injury and/or the communication of infectious disease(s) from one patient to another. Reuse may result in patient complications. • The VersaCross RF Wire must be used with the Connector Cable provided. Attempts to use it with other connector cables can result in electrocution of the patient and/or operator. • Do not use the VersaCross RF Wire with electrocautery or electrosurgery generators, connector cables or accessories as attempted use can result in patient and/or operator injury. • The Connector Cable must only be used with the RFP-100A Baylis RF Generator and the included VersaCross RF Wire. Attempts to use it with other RF Generators and devices can result in electrocution of the patient and/or operator. • The VersaCross RF Wire must be used with 0.035" compatible transseptal sheath and/or dilator devices. Use of incompatible accessory devices may damage the integrity of the VersaCross RF Wire or accessory devices and may cause patient injury. • The VersaCross RF Wire has only been validated for transseptal puncture use through VersaCross dilators which have been demonstrated to provide the required support for optimal function. • The active tip and distal curve of the VersaCross RF Wire are fragile. Be careful not to damage the tip or the distal curve while handling the VersaCross RF Wire. If the tip or the distal curve becomes damaged at any time during its use, discard the VersaCross RF Wire immediately. Do not attempt to straighten the active tip if bent. Damage to device can lead to patient injury. • The VersaCross RF Wire is not intended for use with neonatal patients (i.e. less than one month of age). Do not attempt to treat neonatal patients with the VersaCross RF Wire. • Do not attempt to insert or retract the VersaCross RF wire through a metal cannula or a percutaneous needle, which may damage the device and may cause patient injury.

**PRECAUTIONS:** • Do not attempt to use the VersaCross RF Wire and the Connector Cable before thoroughly reading the accompanying Instructions for Use. • RF puncture procedures should be performed only by physicians thoroughly trained in the techniques of RF-powered puncture in a fully equipped catheterization laboratory. • The sterile packaging should be visually inspected prior to use. Do not use the devices if the packaging has been damaged or compromised. • Visually inspect the VersaCross RF Wire and Connector Cable prior to use to ensure there are no cracks or damage to the insulating material. Do not use the wire or the cable if there is any damage. • Do not use the VersaCross RF Wire and/or Connector Cable after the use-by date indicated on the label. • The VersaCross RF Wire and Connector Cable are intended for use with only those devices listed in Section VIII, Equipment Required. • Read and follow the manufacturer's Instructions For Use for the DIP electrode. Always use DIP electrodes that meet or exceed IEC 60601-2-2 requirements. • Placement of the DIP electrode on the thigh could be associated with higher impedance. • In order to prevent the risk of ignition, ensure that flammable materials are not present in the room during RF power application. • Take precautions to limit the effects that the electromagnetic interference (EMI) produced by the Baylis RF Generator may have on the performance of other equipment. Check the compatibility and safety of combinations of other physiological monitoring and electrical apparatus to be used on the patient in addition to the Baylis RF Generator. • Adequate filtering must be used to allow continuous monitoring of the surface electrocardiogram (ECG) during RF power applications. • Do not attempt to insert and use the proximal end of the VersaCross RF Wire as the active tip. • Do not bend the VersaCross RF Wire or the Connector Cable. Excessive bending or kinking of the wire shaft, distal curve of the wire and/or the Connector Cable may damage the integrity of the device components and may cause patient injury. Care must be taken when handling the VersaCross RF Wire and Connector Cable. • Careful manipulation of the VersaCross RF Wire must be performed to avoid vessel trauma. If resistance is encountered, DO NOT use excessive force to advance or withdraw the VersaCross RF Wire or ancillary sheath and/or dilator assembly. Excessive force may lead to bending or kinking of the device limiting advancement and retraction of sheath and/or dilator device. • VersaCross RF Wire and ancillary sheath and/or dilator assembly advancement should be done under imaging guidance. The use of visible markers on the wire body are only an approximate guide for positioning the wire tip with the distal end of the dilator. • Do not attempt to deliver RF energy until the active tip of the VersaCross RF Wire is confirmed to be in good contact with the target tissue. • Avoid RF energy delivery of the VersaCross RF Wire with incompatible dilator or cannula devices, which may lead to patient burns, ineffective puncture or failure to puncture. • It is recommended not to exceed five (5) RF power applications per VersaCross RF Wire. • Never disconnect the Connector Cable from the Baylis RF Generator while RF power is being delivered. • Never disconnect the Connector Cable from the Baylis RF Generator by pulling on the cable. Failure to disconnect the cable properly may result in damage to the cable. • Do not twist the Connector Cable while inserting or removing it from the Isolated Patient Connector on the Baylis RF Generator. Twisting the cable may result in damage to the pin connectors. • The Baylis RF Generator is capable of delivering significant electrical power. Patient or operator injury can result from improper handling of the VersaCross RF Wire and/or DIP electrode, particularly when operating the device. • During power delivery, the patient should not be allowed to come in contact with ground metal surfaces. • Apparent low power output or failure of the equipment to function properly at normal settings may indicate faulty application of the DIP electrode, failure to an electrical lead, or poor tissue contact at the active tip. Check for obvious equipment defects or misapplication. Attempt to better position the active tip of the VersaCross RF Wire against the atrial septum. Only increase the power if low power output persists. • If using electroanatomical mapping guidance, it is recommended to use it along with alternative imaging modality in the event there is loss of visibility of the device.

**ADVERSE EVENTS:** Adverse events that may occur while creating an atrial septal defect include: • Tamponade • Sepsis/Infection • Thromboembolic episodes • Vessel perforation • Atrial Fibrillation • Myocardial Infarction • Vessel spasm • Sustained arrhythmias • Atrial Flutter • Hemorrhage • Vascular thrombosis • Perforation of the myocardium • Hematoma • Allergic reaction to contrast medium • Ventricular Tachycardia • Pain and Tenderness • Arteriovenous fistula • Pericardial effusion • Tachycardia • Vascular Trauma • Additional Surgical Procedure • Wire entrapment/entanglement • Foreign body/wire fracture

97184047 (REV. B)

All trademarks are property of their respective owners. Patents Pending and/or issued.

**CAUTION:** The law restricts this device to sale by or on the order of a physician. Rx only. Indications, Contraindications, Warnings, and Instructions For Use can be found in the product labelling supplied with each device or at [www.IFU-BSCI.com](http://www.IFU-BSCI.com).

Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

Boston Scientific is a Global Company. Please note that model numbers, indications, contraindications, warnings and specifications may differ depending on geographic region. Not all information displayed in this brochure may be licensed in accordance with Canadian law. Please contact your Boston Scientific representative for local labeling, product specifications and licensed model numbers.

**Boston  
Scientific**  
Advancing science for life™

© 2024 Boston Scientific Corporation  
or its affiliates. All rights reserved.

EP-1841105-AA